This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos?
by Kanishka Das
Precigen's Papzimeos is gaining commercial momentum, while its pipeline potential through the AdenoVerse platform could create new growth opportunities.
PGENPositive Net Change MRKNegative Net Change INONegative Net Change
biotechs
Beyond Imbruvica: Can AbbVie Rebuild Its Oncology Portfolio?
by Sundeep Ganoria
ABBV is expanding its oncology pipeline with newer therapies and diverse approaches to offset Imbruvica's decline.
ABBVPositive Net Change AZNNegative Net Change PFEPositive Net Change MRKNegative Net Change
biotechs medical pharmaceuticals
ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data
by Zacks Equity Research
Oruka's ORKA-001 delivers deeper psoriasis clearance at week 28, but safety disclosures may have weighed on shares despite positive efficacy data.
ORKANegative Net Change ALDXNegative Net Change ACIUPositive Net Change PGENPositive Net Change
biotechnology biotechs medical pharmaceuticals
Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs
by Zacks Equity Research
IONS posts positive phase III results for two partnered drugs, with ulefnersen meeting its ALS endpoint and sefaxersen cutting proteinuria.
IONSPositive Net Change AZNNegative Net Change NVSPositive Net Change RHHBYNegative Net Change
biotechs medical pharmaceuticals
Can LQDA's Yutrepia Outpace Intensifying PAH Competition?
by Ekta Bagri
Liquidia's Yutrepia posts rapid sales growth, but intensifying competition from established therapies and emerging drugs could test its momentum.
LQDAPositive Net Change UTHRPositive Net Change INSMNegative Net Change
biotechnology biotechs medical pharmaceuticals
VKTX Stock Rises on Encouraging Weight-Loss Maintenance Results
by Zacks Equity Research
Viking Therapeutics' shares jump 36% as VK2735 maintenance data show most weight loss is preserved with less-frequent dosing.
VKTXNegative Net Change NVONegative Net Change LLYPositive Net Change
biotechs medical pharmaceuticals
AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study
by Zacks Equity Research
Amgen's dazodalibep meets its primary goal in a Phase III study, showing sustained improvement in systemic Sjogren's disease activity through week 48.
AMGNPositive Net Change RGENPositive Net Change ANIKPositive Net Change PGENPositive Net Change
biotechs
Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1?
by Ahan Chakraborty
NVO's rare disease pipeline gains momentum as Frehemgo and Sogroya receive positive CHMP opinions for EU approval, opening new growth opportunities beyond GLP-1.
NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte
by Zacks Equity Research
Four biotech companies face key fall readouts that could influence the development and commercial prospects of their pipelines.
CLDXPositive Net Change KODPositive Net Change PCVXPositive Net Change RAPPNegative Net Change
biotechnology biotechs
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce
by Zacks Equity Research
INSM's Arikayce label expansion gets FDA priority review, potentially broadening its use in newly diagnosed MAC lung disease.
INSMNegative Net Change ACIUPositive Net Change PGENPositive Net Change
biotechs medical